Dr. Tongtong Zhao is an award-winning scientist and biotech innovator with deep expertise in genomics, oncology, and cellular engineering, and a track record of advancing concepts from discovery to application.
Her academic research at Cambridge, Harvard, and the Broad Institute yielded foundational insights in cell biology, neuronal signaling, and tumor evolution, resulting in first-author publications in Science and Nature, as well as co-authorship on other high-profile studies. At the Broad Institute, she developed new spatial and single-cell genomic technologies that bridged computation, engineering, and translational biology, contributing to licensed IP and reshaping how tumor heterogeneity can be studied in patient tissues.
Tongtong was the first scientist at Xap Therapeutics, where she translated an innovative early scientific vision into an emerging in vivo gene therapy platform. She helped build the company’s R&D capabilities from the ground up, directed programs spanning discovery and translational biology, and delivered critical data that secured successive rounds of venture funding. She is also an experienced team builder and mentor, committed to fostering culture and guiding early-career scientists.
Following her undergraduate studies at Imperial College London and Heidelberg University, where she graduated as top student of her year, Tongtong earned her PhD in Genetics at the University of Cambridge. Working at the Wellcome Trust Gurdon Institute, she developed new mRNA-labeling assays, collaborated with biophysicists and engineers to quantify intracellular forces, and served as a Teaching Fellow in Cell and Developmental Biology at Cambridge. She subsequently pursued postdoctoral training at Harvard Medical School, characterizing a new pathway by which mitochondrial damage and hypoxia alter neurotransmission and behavior, and connected industry leaders, investors, and scientists around collaborative, high-impact programs as part of the MGH Research Institute’s Strategic Alliance Initiative.
Her work has been recognized with highly competitive awards, including the Human Frontier Science Program and Jane Coffin Childs postdoctoral fellowships, as well as the Boehringer Ingelheim Fonds and FAZIT Foundation PhD fellowships.
Pasha Sarraf, MD, PhD
Dr. Pasha Sarraf is a devoted physician-scientist with deep leadership experience across the business of life sciences, from pharma, to biotech, to Wall Street. His incisive decision-making ensures future value creation on every project he works on.
Read BioAndrew N Schwartzberg
Andrew Schwartzberg is one of the leading affordable housing developers in the United States and an active investor in companies focused on advancements in the life sciences.
Read BioAaron Day-Williams, PhD
Dr. Aaron Day-Williams is a highly respected and collaborative computational geneticist and biologist who excels at transforming quantitative assessments of therapeutic hypotheses into actionable target identification, validation, and clinical development.
Read BioDylan Dupuis, PhD
Dr. Dylan Dupuis is an experienced biotech analyst who skillfully applies qualitative and quantitative thinking to identify exceptional value in life sciences opportunities.
Read BioJames Patterson, MD, PhD
Dr. James Patterson is an inventive physician-scientist and networked entrepreneur, skillfully founding, fundraising, and leading R&D efforts to create impactful therapeutics.
Read BioNathan Edwards
Nathan Edwards has deep expertise in tactical and strategic financial management spanning project incubation to commercial launches, with a proactive and disciplined approach to portfolio optimization.
Read BioNathan Post
Nathan Post is an operator experienced in building, scaling, and transforming biotechnology companies across a range of private investment stages.
Read BioTongtong Zhao, PhD
Dr. Tongtong Zhao is a distinguished scientist and biotech innovator whose expertise spans analytical rigor, foundational research, and technology development central to company building.
Read Bio